Banco Santander S.A. reduced its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 23.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 67,467 shares of the pharmacy operator's stock after selling 21,171 shares during the quarter. Banco Santander S.A.'s holdings in CVS Health were worth $4,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of the business. MidAtlantic Capital Management Inc. purchased a new stake in shares of CVS Health during the 3rd quarter valued at about $25,000. Livelsberger Financial Advisory purchased a new stake in CVS Health in the third quarter worth approximately $31,000. Reston Wealth Management LLC bought a new stake in CVS Health in the 3rd quarter worth approximately $32,000. First Community Trust NA lifted its holdings in shares of CVS Health by 116.2% during the 2nd quarter. First Community Trust NA now owns 562 shares of the pharmacy operator's stock valued at $33,000 after buying an additional 302 shares during the period. Finally, Kathleen S. Wright Associates Inc. purchased a new position in shares of CVS Health in the 3rd quarter worth $33,000. 80.66% of the stock is currently owned by institutional investors.
Shares of CVS Health stock opened at $57.07 on Friday. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The firm has a market cap of $71.81 billion, a price-to-earnings ratio of 14.48, a PEG ratio of 0.94 and a beta of 0.55. CVS Health Co. has a twelve month low of $52.71 and a twelve month high of $83.25. The business has a 50-day moving average price of $59.20 and a 200-day moving average price of $58.60.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.01. The business had revenue of $95.43 billion for the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The company's revenue was up 6.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.21 EPS. Equities research analysts anticipate that CVS Health Co. will post 5.43 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 annualized dividend and a yield of 4.66%. CVS Health's dividend payout ratio (DPR) is currently 67.51%.
A number of research analysts have weighed in on CVS shares. Barclays lowered their target price on CVS Health from $75.00 to $71.00 and set an "overweight" rating on the stock in a report on Thursday, November 7th. Wells Fargo & Company raised shares of CVS Health from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $60.00 to $66.00 in a report on Monday. Evercore ISI upped their target price on shares of CVS Health from $62.00 to $75.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Mizuho cut their price objective on shares of CVS Health from $73.00 to $66.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Finally, Royal Bank of Canada lowered their target price on CVS Health from $68.00 to $58.00 and set an "outperform" rating on the stock in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, CVS Health has an average rating of "Moderate Buy" and an average price target of $72.28.
Get Our Latest Stock Report on CVS
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.